Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administration (FDA) regarding its Nellix(R) Endovascular Aneurysm Sealing System (the Nellix(R) EVAS System).
We are going to take a close look at Endologix Inc. (NASDAQ:ELGX) today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today’s focus will be a fundamental evaluation of the stock from top to bottom.
As such, let’s start with the top line: Revenue trends.
Last quarter, the company saw its overall sales move to $47.46M in total revenues. That represents an overall change in revenues, on a quarterly year/year basis, of 0.17%. If we translate that into sequential terms, the company saw sales decline by -0.1% from quarter to quarter.
While revenue analysis gives us a strong sense of changing demand trends in the company?s end market, and how the company is executing in terms of its relationship with potential customers, real shareholder value is only truly created by profitability.
With this in mind, we turn to the company’s bottom line data.
Endologix Inc. (NASDAQ: ELGX) is intriguing when broken down to its core data. The cost of selling goods last quarter was $18M, yielding a gross basic income of $29.46M. For shareholders, given the total diluted outstanding shares of 82.69M, this means an overall earnings per share of $(0.30). Note, this compares with a consensus analyst forecast of $-0.15 in earnings per share for its next fiscal quarterly report.
Next, let’s look ahead at coming performance based on what analysts are projecting for the company more generally, before closing with a survey of the balance sheet and cash flow.
At present, analysts hold a consensus average recommendation of Overweight. This is based on a total of 10 analysts? ratings. While we don’t suggest taking analyst recommendations as face value plans for action in a portfolio, we do think it is important to note where consensus is on a stock to understand what basic assumptions are perhaps already discounted into market pricing of shares of the stock.
As far as price targets, analysts currently have an average target on shares of at $8.25. In addition, if we turn to next year, we see estimates of a fiscal year forecast to bring about -0.40 in total earnings per share. On a median price to earnings ratio basis, that outlook adds up to a valuation of 9,999 times earnings.
So far, we have covered how the company is doing on both the top and bottom line, as well as what professional analysts believe about its core trends and operational and financial performance going forward. However, we would be remiss if we did not also take a quick look at cash flows and the company’s balance sheet to round out our perspective on the name.
The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend. The market is in highly oversold territory. Beware of a trend reversal.
As the reader is no doubt aware, for any company, balance sheet health sits at the heart of the company’s capacity to stand up to the demands and obligations incurred by normal and contingent operations, which in turn lies at the core of a company’s ability to retain the faith of investors in the marketplace. For Endologix Inc. (NASDAQ:ELGX), the company presently holds about $28.12M in cash in the coffers. That cash is balanced against about $- in total current liabilities.
It’s important to consider both a static and dynamic picture, particularly where debt levels are concerned. This means, we need to take into account any trends. In this case, the company?s debt has been $falling. The company also has $359.68M in total assets, balanced by $246.89M in total liabilities, which suggests where this story might go under adverse economic or financial conditions.
As far as cash flows, the company saw a free cash flow last quarter of $(15.48M), representing a quarterly net change in cash of $4.1M. On a net operating level, the company saw about $(14.74M) in cash flow.
We will update the interesting story of Endologix Inc. (NASDAQ: ELGX) as new events transpire.